An experimental treatment for Hepatitis C was, as reported by scientists at the Southwest Foundation for Biomedical Research, was successfully able to curb the spreading of virus in the bloodstream of chimpanzees, and might just be good enough to treat chronic infections in human beings as well. The study was put forward on Thursday.

As per the researchers, the treatment works by curbing a molecule which is mainly responsible for the replication of Hepatitis C, and the good news is that the medicine continued to work up-to several months after the treatment's completion.

"The treatment is already undergoing human clinical trials and is currently undergoing Phase 1 clinical study in healthy volunteers", the researchers said.

The first drug of its type to actually see a human test, it is currently being referred to as SPC3649, and has been developed by the Danish biopharmaceutical firm Santaris Pharma.

"Our collaboration with Santaris Pharma proved that the drug worked exceptionally well in treating HCV infections in chimpanzees", the researchers shared, while asserting that if proved successful, the technology could also be employed in a treatment of various other dangerous and chronic diseases including cancer, HIV and many inflammatory conditions.

The study has been published in the December 3 issue of the journal Science Express.